Efficacy of Trimetazidine Dihydrochloride for Relieving Chronic Tinnitus: A Randomized Double-Blind Study
Clinical and Experimental Otorhinolaryngology
;
: 192-197, 2016.
Artículo
en Inglés
| WPRIM
| ID: wpr-188147
ABSTRACT
OBJECTIVES:
To evaluate the efficacy of trimetazidine dihydrochloride as a treatment for chronic tinnitus.METHODS:
A total of 97 chronic tinnitus patients were evaluated in this randomized, prospective, double-blind, placebo-controlled trial. After assessing for eligibility, 82 patients were randomly assigned into placebo or trimetazidine groups according to the medication. The trimetazidine group received 20×3 mg/day per oral trimetazidine dihydrochloride and the placebo group received 20×3 mg/day per oral placebo for 3 months. Tinnitus handicap inventory (THI), visual analogue scale (VAS) questionnaires and audiometric results were used to determine the effectiveness of trimetazidine treatment.RESULTS:
The study group comprised 82 tinnitus subjects, 42 (51%) of whom received trimetazidine dihydrochloride and 40 (49%) who received placebo. There was no significant difference between placebo and trimetazidine groups in THI grade and VAS (both pre- and posttreatment scores) (P>0.05) and no significant improvement was observed in subjective loudness score in either group (P>0.05). Additionally there was no significant difference between groups in pre- and posttreatment pure tone hearing thresholds at all measured frequencies (P>0.05).CONCLUSION:
Trimetazidine dihydrochloride therapy was ineffective for relieving chronic tinnitus.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Acúfeno
/
Trimetazidina
/
Método Doble Ciego
/
Estudios Prospectivos
/
Audición
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio observacional
Límite:
Humanos
Idioma:
Inglés
Revista:
Clinical and Experimental Otorhinolaryngology
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS